Literature DB >> 12627855

Clinical significance of fragmented red cells after allogeneic bone marrow transplantation.

Heiwa Kanamori1, Yumiko Takaishi, Maki Takabayashi, Masatsugu Tanaka, Satoshi Yamaji, Naoto Tomita, Katsumichi Fujimaki, Shin Fujisawa, Shinichiro Watanabe, Michio Matsuzaki, Yoshiaki Ishigatsubo.   

Abstract

To clarify the clinical significance of the presence of fragmented red cells (FRC) after allogeneic bone marrow transplantation (BMT), we measured the incidence and degree of FRC and their relationships to clinical features. The percentages of FRC (%FRC) were measured in 50 patients on weeks -2, 0, 2, 4, 6, 8, 10, and 12. The %FRC in pre-BMT patients (mean, 0.52%; range, 0.04%-1.56%) was higher than in healthy control subjects (mean, 0.08%; range, 0.02%-0.27%). The highest %FRC (> or = 1.3%) were seen in 2 pre-BMT and 17 post-BMT patients. Eight patients who developed thrombotic microangiopathy (TMA) showed %FRC values that were significantly higher than those in patients without TMA. However, the timing of elevated %FRC was delayed until several days after the onset of intravascular hemolysis and/or a drop in platelet count. Of the patients who did not experience TMA, 5 patients with infection and 4 patients with acute graft-versus-host disease (GVHD) also showed significant elevation of %FRC during the clinical course. Furthermore, multivariate analysis results demonstrated that TMA and infection had a statistically significant effect on the high value of %FRC. These findings indicate that the appearance of FRC is a common phenomenon in patients undergoing BMT and is not a predictive factor for the early diagnosis of TMA, although FRC is one of the main laboratory findings in TMA. Furthermore, an increased %FRC is seen in other post-BMT clinical settings, such as infection and acute GVHD.

Entities:  

Mesh:

Year:  2003        PMID: 12627855     DOI: 10.1007/bf02983218

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  15 in total

1.  Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies.

Authors:  S N Rabinowe; R J Soiffer; N J Tarbell; D Neuberg; A S Freedman; J Seifter; K W Blake; J G Gribben; K C Anderson; T Takvorian
Journal:  Blood       Date:  1991-04-15       Impact factor: 22.113

2.  The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation.

Authors:  R Fuge; J M Bird; A Fraser; D Hart; L Hunt; J M Cornish; N Goulden; A Oakhill; D H Pamphilon; C G Steward; D I Marks
Journal:  Br J Haematol       Date:  2001-04       Impact factor: 6.998

3.  Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation.

Authors:  S Testa; A Manna; A Porcellini; F Maffi; G Morstabilini; N Denti; S Macchi; G Rosti; G Porcellini; D Cassi; L Ferrari
Journal:  Bone Marrow Transplant       Date:  1996-08       Impact factor: 5.483

4.  Coagulation abnormalities and thrombotic microangiopathy following bone marrow transplantation from HLA-matched unrelated donors in patients with hematological malignancies.

Authors:  T Natazuka; K Kajimoto; R Ogawa; S Imoto; T Koizumi; R Nishimura; T Nakagawa
Journal:  Bone Marrow Transplant       Date:  1998-04       Impact factor: 5.483

5.  Haemolytic uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation?

Authors:  M E Chappell; D M Keeling; H G Prentice; P Sweny
Journal:  Bone Marrow Transplant       Date:  1988-07       Impact factor: 5.483

6.  Red cell fragmentation (schistocytosis) after bone marrow transplantation.

Authors:  A Zomas; R Saso; R Powles; H Mackay; S Singhal; J Treleaven; J Mehta
Journal:  Bone Marrow Transplant       Date:  1998-10       Impact factor: 5.483

Review 7.  Thrombotic microangiopathy following bone marrow transplantation.

Authors:  A R Pettitt; R E Clark
Journal:  Bone Marrow Transplant       Date:  1994-10       Impact factor: 5.483

8.  Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation.

Authors:  E Holler; H J Kolb; E Hiller; W Mraz; W Lehmacher; B Gleixner; C Seeber; U Jehn; H H Gerhartz; G Brehm
Journal:  Blood       Date:  1989-05-15       Impact factor: 22.113

9.  Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: a new treatment strategy.

Authors:  F M Jeejeebhoy; J S Zaltzman
Journal:  Transplantation       Date:  1998-06-27       Impact factor: 4.939

10.  Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.

Authors:  P Kalhs; S Brugger; I Schwarzinger; H T Greinix; F Keil; P A Kyrle; P Knöbl; B Schneider; P Höcker; W Linkesch
Journal:  Transplantation       Date:  1995-11-15       Impact factor: 4.939

View more
  3 in total

Review 1.  Transplant-associated thrombotic microangiopathy: opening Pandora's box.

Authors:  E Gavriilaki; I Sakellari; A Anagnostopoulos; R A Brodsky
Journal:  Bone Marrow Transplant       Date:  2017-03-13       Impact factor: 5.483

2.  Bone marrow transplant-associated thrombotic microangiopathy without peripheral blood schistocytes: a case report and review of the literature.

Authors:  Eric Wirtschafter; Christine VanBeek; Yuliya Linhares
Journal:  Exp Hematol Oncol       Date:  2018-06-22

Review 3.  Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis.

Authors:  Joanna A Young; Christopher R Pallas; Mary Ann Knovich
Journal:  Bone Marrow Transplant       Date:  2021-04-19       Impact factor: 5.174

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.